Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

Table 2

Retrospective studies showing poor correlation between neutropenia and neutropenic complications.

Author	Number of analyzed patients without G-CSF	Grade 4 neutropenia (%) patients/treatments^1	% of febrile neutropenia^2	% of growth factor supported treatments	DM^3 due to grade 3 or 4 neutropenia
Chand et al.	81	43/7	1.0	6.5	15.5% of all treatments
Evens et al.	59	26/NA^4	0.44	0	None
Boleti and Mead	28	37/NA	0.57	0	None
Nangalia et al.	24	NA/18	0.76	0	None

1. Treatments are half cycles, that is, two treatments per cycle.
2. Incidence of febrile neutropenia as percentage of overall treatments (half cycles).
3. DM: dose modification.
4. NA: not available.